Correo Electrónico
DNINFOA - SIA
Bibliotecas
Convocatorias
Identidad U.N.
Publicado
Radiopharmaceutical drug interactions
Interacciones medicamentosas con radiofarmacéuticos
Palabras clave:
Review, systematic, drug safety, radiopharmaceuticals (en)Revisión, interacción, radiofármacos (es)
Descargas
There has been considerable under-reporting of drug and radiopharmaceutical interactions, security and adverse reactions. The increasing use of radiopharmaceuticals has come to the attention of nuclear medicine staff and regulatory bodies. The aim is to provide reference for adverse reactions which could help all nuclear medicine staff in their daily routine. Reporting adverse events, including situations where an adverse event may have occurred but was actually avoided, is essential when assessing the magnitude of problems, alerting health professionals to these problems and ultimately for improving diagnostic accuracy.
Se ha identificado que la información sobre la interacción entre medicamentos y radiofármacos es considerablemente insuficiente. El incremento en la utilización de radiofármacos ha llamado la atención de los grupos de medicina nuclear y los organismos reguladores. El objetivo es proporcionar información que podrían ayudar a los grupos de medicina nuclear en su rutina diaria, sobre las reacciones adversas. Presentación de informes de eventos adversos, incluidas las situaciones en que un acontecimiento adverso podría haber ocurrido, pero se evitó, es esencial para evaluar la magnitud de los problemas, alertar a los profesionales de la salud sobre estos problemas y, en definitiva, para mejorar la precisión diagnóstica.
Referencias
Tewson TJ, Krohn K.A. Pet radiopharmaceuticals: state-of-the-art and future prospects. Seminars in Nucl. Med.1998; 28(3) 221-234.
Hessllewood S, Leung, E. Drug interaction with radiopharmaceuticals. Eur. Jour. Nucl.Med. 1998; 21 (4): 348-356.
Sampson CB, Hesselwood SR. Altered biodistribution of radiopharmaceuticals as a result of pharmacological or chemical interaction, J. Biopharm. 1989; 5: 131-151.
Sampson CB. Adverse reactions and drug interaction with radiopharmacuticals. Drug safety. 1993; 8 (4): 280-294.
Sampson CB. Drugs and chemicals wich affect the purity, biodistribuition and pharmacokinetics of radiopharmaceuticals. J. Biopharm Sci. 1990; 1(4):381-400.
Callaham RJ, Rabito CA. Radiolabeling of erythrocytes with technetium-99m: role of band-3 protein in the transport of pertchnetate across the cell membrane. J. Nucl. Med.1990; 31:2004-2010.
Fisher S,; Brown RG, Greyson ND. Unbinding of tc-99m by iodinated antiseptics. J. Nucl. Me.1977; 18:1139-1140.
Slater DM, ANDERSON M, Garvie NW. Syringe extractables, effects on radiopharmaceuticals. Lancet.1983; 2:1431-1431.
Millar A,; Wathem CJ, Muir AL. Failure in labelling of red cells with tc-99: interaction between intravenous cannulae and stannous pyrophosphate. Eur J Nucl Med.1983; 8: 502-504.
Vidal MV, Gutfilen B, Barbosa da Fonseca LM et al. Influence of tobacco on the labelling of red blood cells and plasma proteins with technetium-99m J. Exp. Clin. Cancer Res. 1998; 17:. 41-46.
Solanki KK, Bomanji J, Moyses J, Mather SJ, Trainer, PJ, Britton, KE. A pharmacological guide to medicines wich interfere with the biodistribution of radiolabelled meta-iodobenzyl-guanidine (MIBG). Nucl. Med Commun.1992; 13: 513-521.
Hladik W, Saha, BG. Study KT, eds essentials of nuclear medicine science, Ed. Wiliams and Wilkins, Nueva York, pp. 180-220, 1987.
Fischer M, Vetter W, Winterg B, Zidek W, Vetter H. Adrenal scintigraphy in primary aldosteronism. Spironolactona as a cause of incorrect classification between adenona and hyperplasia. Eur J Nucl Med. 1982; 7: 222-224.
Khafagi F, Shapiro B, Lorraine M, Mallette S, Sisson JC. Labetolol reduces iodine-131-mibg uptake by pheochromacytom and normal tissues. J.Nucl.Med. 1989; 30 (4): 481- 489.
Gross MD, Valk, TW, Swanson D P, Thrall, JH, Grekin RJ, Beirewaltes, WH. The role of pharmacologic manipulation in adrenal cortical scintigraphy. Semin. Nucl Med. 1981; 11: 128-148.
Bardet S, Rohmer V, Murat A, Guillemot C, Marechaud R, Chupin M, et al. 131-6-ß- Iodomethylnorcholesterol scintigraphy: an assessment of its role in the investigation of adrenocortical incidentalomas. Clinical Endocrinology. 1996; 44 (5): 587-596.
Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein, SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocrine Reviews. 2004; 25 (2): 309-340.
Swanson D P, Chilton HM, Thrall JH Pharmaceuticals in medical imaging. Ed. Macmillan, Nova York, 1990.
Verhoeff NPLG. Pharmacological implications for neuroreceptor imaging. Eur. J. Nucl. Med. 1991; 18: 482-502.
Lentle BC, Scott JR. Iatrogenic alterations in radionuclide biodistribuition. Semin Nucl. Med.1979; 9: 131-134.
Waxman AD, Beldon JR; Richli WR, Tanasescu DE, Siemsen JK. Steroid induced supression of gallium uptake tumours of the central nervous system. J. Nucl. Med. 1997; 18: 617-617.
Sandler ED, Parisi Mt, Hattmer RS. Duration of etidronate effect demonstrated by serial bone scintigraphy. J. Nucl. Med. 1991; 32: 1782-1784.
Hommeyer SH, Varney DM, Eary JF. Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy. J. Nucl. Med.1992; 33:748-750.
Crawford JA. Alteration of body distribution of 99m tc-pyrophosphate by radiographic contrast material. Clin. Nucl. Med. 1978; 3: 305-307.
Mazzole AC, Barker, MM, Belliveal RE. Accumulation of tc-99m-diphosphonate at sites of intramuscular iron therapy. J. Nucl.Med & Tech. 1976; 4: 133-135.
Miygawa M, Tanada S, Hamamoto K. Scintigraphic evaluation of myocardial uptake of thallium 201 and technetium 99m pyrophosphate utilizing a at model of chronic doxorubicin cardiotoxicity. Eur. J Nucl. Med.1991; 18: 332-338.
Yurekli Y, Unak P, Ertay T, Biber Z, Medine I, Teksoz, S. Radiopharmaceutical model using 99mtc-mibi to evaluate amisfostine protection aginst doxorubicin cardiotoxicity in rats. Annals Nucl. Med.2005; 19: 197-200.
Moreno SRF, Silva ALC, Diré G, Honeycut H, Carvalho JJ, Nascimento AL, et al.. Effect of oral ingestion of an extract of the herb uncaria tomentosa on the biodistribution of sodium pertechnetate in rats. Braz. J Med Biol Res. 2007;.40 (1): 77-80.
Bridges AB, Kennedy N, Mcneill G P, Cook B, Pringle TH. The effect of atenolol on dipyridamole tl-20 myocardial perfusion tomography in patients with coronary artery disease. Nucl. Med Commun.1992; 13: 41- 46.
Chacko AK, Gordon DH, Bennet JM, O'Mara RE, Wilson GA. Myocardial imaging with tc-99m pyrophosphate in patients on adiamycin treatment for neoplasia. J Nucl Med.1977; 18: 680-683.
HEegge FN, Hamilton GW, Larson SM. Cardiac chamber imaging: a comparison of red blood cells labelled with tc-99m in-vitro an in-vivo. J. Nucl.Med.1978; 19: 129-134.
Gomes ML, Mattos DMM, Souza-Freitas R et al. Study of the toxicological effect of mitomycin c in mice: alteration on the biodistribution of radiopharmaceuticals used for renal evaluations. Human & Experimental Toxicology. 2001; 20:.193-197.
Estorch M, Carrio I; Berna L, Martinez-Duncker C, Alonso C, Germá JR, et al.. Indium-111 antimyosin scintigraphy after doxorubicin theraphy in patientes with advanced breast cancer. J Nucl Med. 1990; 31: 1965-1969.
Reuland P, Ruck P, Feine U. Correlation of chemotherapy-induced kdney disorder and antimyosin antibody uptake in kidneys. J Nucl Med. 1992; 33: 309-311.
Carrio I, Lopez-Pousa J, Duncker D. Comparison of cardiotoxicity bu in-111 antymioyosin studies:bolus administration versus continuos infusion of doxorubicin. Eur J Nucl Med. 1993; 20: 833-834.
Sheng Y, Bryngelsson C, Pero RW. Enhanced Dna repair, immune function and reduced toxicity of C-MED-100, a novel aqueous extract from Uncaria tometosa. J. Ethnoparmacol.2000; 60:115-126.
Williams JE. Review of antiviral and immunomodulating properties of plants of the Peruvian rainforest with particular emphasis on uña de gato and sangre de gadro. Altern Med. Rev.2001; 6:567-579.
Pope R, Bratke J. Two tec-99mhda cases with delayded emtying into the doudenum.1981; Monthly scan:College of Pharmacy, New Mexico, Monthly Newsletter, may/june.
Feezer EA. Hepatobiliary imaging: general considerations. The view box, july issue, Dep. Nucl. Med, Wesley Medical Centre, Kansas, 1982.
Hinkle GH, Basmadjian G P, Peek C, Barker KK, Ice RD. Effects of concurrent drug therapy on technetium tc-99m gluceptate biodistribution. American Journal of Hospital Pharmacy,.1982; 39:1930-3.
Chung CJ, Hicklim OA, Payan JM, Gordon L. Indium-111-labeled leukoccyte scan in detection of synthetic vascular graft infection: the effect of antibiotic treament. J Nucl Med.1991; 32: 13-15.
Datz FL, Thorne DA. Effect of antobiotic therapy on the sensitivity of indium-111-labelled leukocyte scans. J Nucl Med. 1986; 27: 1849-1853.
Latham TB, Prato F, WIisenberg G, Reese L. Effects of dipyrdamole infusion on human renal function observed using technetium-99m-dtpa. J.Nucl.Med.1992; 33: 355- 358.
Bobbinet EB, Severin M, Zurbriggen MT. Lung uptake of tc-99m sulphur colloid in patients exhibiting presence of aluminium in plasma. J. Nucl.Med. 1974; 15: 1120-1222.
Sternthal E, Lipwith G, Starling B. Supressing of thryoid radioiodine uptake by various doses of stable iodine. New England J. Med.1980; 303: 1083-1088.
Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM, et al . Scintigraphic localization of pheochromocytoma. N. Eng. J. Med. 1981; 305:12-1.
Horne T, Hawkings LA, Britton KE, Granowska M, Bouloux P, Besser GM. Imaging of phaeochromocytoma and adrenal medulla with 123 I-metaiodobenzylguanidine. Nucl.Med.Commun. 1984; 5: 763-768.
Fischer M, Winterberg B et al. Radioisotopic therapy of pheochromocytoma. Nucl. Compact, 14 :. 172-6, 1983.
Kimming B, Braneis WE,; Eisenhunt M et al. Scintigraphy of a neuroblastomas with 131 i mibg. J. Nucl. Med. 1984; 25: 773-775.
Bomanji J, Levinson, DA, Zuzarte, J et al. Imaging of carcinoid tumors with 123i-mibg. J. Nucl.Med 1987; 28:1907-1910.
Stone T, Fukunaga M, Otsuka N et al. Metasttatic medullary thyroid cancer, localisation with 131-i-mibg. J. Nucl.Med. 1985; 26: 604-8.
Dorr U, Rath U, Sauttter-Bihl M-L et al. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med 1993; 20: 431-433.
Cómo citar
APA
ACM
ACS
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver
Descargar cita
Visitas a la página del resumen del artículo
Descargas
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Esta revista provee acceso libre inmediato a su contenido bajo el principio de que hacer disponible gratuitamente investigación al publico apoya a un mayor intercambio de conocimiento global.
Todos los contenidos de esta revista, excepto dónde está identificado, están publicados bajo una Licencia Creative Commons Atribución 4.0.
